According to the National Cancer Institute, surveillance for multiple endocrine neoplasia type-1 by imaging studies such as brain MRI, abdominal CT, and abdominal MRI is recommended every 3-5 year among patients with pituitary tumors and pancreatic neuroendocrine tumors respectively. Biochemical tests such as serum prolactin, insulin-like growth factor 1, fasting total serum calcium, ionized calcium, parathyroid hormone, fasting serum gastrin, chromogranin A, pancreatic polypeptide, glucagon and vasoactive intestinal polypeptide are recommended every year for patients with pituitary tumors,  pancreatic neuroendocrine tumors, and primary hyperparathyroidism.
Multiple endocrine neoplasia type 1 secondary prevention
Multiple endocrine neoplasia type 2 secondary prevention
Multiple endocrine neoplasia type 2 prevention
Multiple endocrine neoplasia type 2 future or investigational therapies
Multiple endocrine neoplasia type 1 future or investigational therapies
Multiple endocrine neoplasia type 2 medical therapy
Multiple endocrine neoplasia type 1 medical therapy
Addison's disease secondary prevention